RVT-104

RVT-104 is a proposed combination of a higher than currently approved dose of the cholinesterase inhibitor rivastigmine and a peripherally active muscarinic receptor antagonist as a potential treatment for patients with Alzheimer's disease and dementia with Lewy bodies (DLB).